Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simotang oral liquid for gastrointestinal recovery after abdominal surgery under ERAS
ChiCTR2200065942Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Start
- Aug 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of simotang in Postoperative gastrointestinal dysfunction (POGD) (4 arms), sponsored by Jiangsu Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Time for resuming oral half-flow diet and maintaining good tolerance for 48 hours. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
simotang
03
Conditions
Postoperative gastrointestinal dysfunction (POGD)
Beyond the preview
Go deeper on ChiCTR2200065942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065942.